Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome

ConditionsEndocan Copeptin Serum Preterm Neonates Respiratory Distress Syndrome

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age28-36

SponsorTanta University

About this trial

This work aims to investigate and compare the levels of serum endocan and serum copeptin on the first day of life and correlate their levels to the severity of respiratory distress in preterm neonates suffering from respiratory distress syndrome.

Eligibility criteria

Qualifiers

Prematurity.

Gestational age between 28 and 36 weeks.

Suffering from respiratory distress syndrome.

Disqualifiers

Intrauterine growth restriction (IUGR).

Hypoxic ischemic encephalopathy.

Multiple congenital anomalies.

Chromosomal abnormalities.

Trial design

Treatments tested in this trial

Serum endocan
Serum copeptin

Treatment groups

40 Participants

are divided into 2 treatment groups

Locations

Tanta University31527, TantaEl-Gharbia, Egypt

Sponsors and collaborators

Tanta University

Lead sponsor

Source ClinicalTrials.gov